HER2 overexpressed breast cancers are accounting for 15 to 20% of breast cancers [1], and strongly benefit from anti-HER2 treatment mainly trastuzumab-based chemotherapies [2, 3]. This evidence concerns the gene ERBB2 and breast carcinoma.